EU authorizes Pfizer-BioNTech XFG-adapted COVID vaccine for ages 6 months and up
Complete. Here is the key summaryThe European Commission has granted marketing authorization for Pfizer-BioNTech’s 2026-2027 monovalent COVID-19 vaccine targeting the XFG variant. The approval covers individuals aged 6 months and older across all 27 EU member states, as well as Iceland, Liechtenstein, and Norway. Shipments are expected to commence shortly as manufacturing scales up ahead of the respiratory season.
- European Commission granted marketing authorization for Pfizer-BioNTech’s 2026-2027 monovalent COVID-19 vaccine targeting the XFG variant in the EU. * Clearance covers people aged 6 months and older across all 27 EU member states, Iceland, Liechtenstein, Norway. * Shipments expected to start soon as manufacturing ramps ahead of the respiratory season. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Pfizer Inc. published the original content used to generate this news brief on July 29, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT) Original Document: here